Skip to main content
OpenTrials
Completed

NCT Number: NCT07774117

CyanthOx™ Capsule Efficacy Study

The goal of this clinical trial is to learn whether daily intake of CyanthOx™80 capsules can improve skin, scalp, hair, and selected blood biomarkers in healthy adults after 12 weeks.

Researchers will compare participants who take CyanthOx™80 with participants who take a placebo to evaluate its effectiveness and tolerability.

A total of 40 participants will be randomly assigned to the CyanthOx™80 group or placebo group, with 20 participants in each group. Participants will not know which capsule they receive.

Participants will:

Take one capsule daily for 12 weeks. Attend study visits at baseline and weeks 4, 8, and 12. Undergo non-invasive facial skin assessments at baseline, week 4, and week 12. Undergo scalp and hair assessments at baseline and weeks 4, 8, and 12. Provide a 10 mL blood sample at baseline and week 12 for tests related to antioxidant capacity, inflammation, aging, collagen, and blood lipids.

Complete questionnaires about skin condition and product satisfaction. Provide collected shed hair at weeks 4, 8, and 12. Have facial, scalp, and hair photographs taken. Identifiable areas will be masked before disclosure.

Before each skin or scalp assessment, participants will cleanse the test area with water and rest at room temperature for 30 minutes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Skin Aging Alopecia Hair Diseases Hair Loss Hair and Scalp Health Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Chia Nan University of Pharmacy ＆ Science

Tainan, Taiwan, 71710

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants aged over 18 years.

Exclusion criteria

  • Individuals who are unwilling to participate voluntarily.
  • Individuals diagnosed by a physician with skin disease, liver cirrhosis, or chronic renal failure.
  • Individuals with known allergies to cosmetics, drugs, or foods.
  • Pregnant or breastfeeding individuals.
  • Individuals taking medications for chronic diseases.
  • Students taught by the principal investigator.
  • Individuals unwilling to allow their study-related photographs to be disclosed. Vegetarians.

Treatment and study plan

Placebo Group

Dietary Supplement

Participants will take one placebo capsule daily for 12 weeks.

CyanthOx™80 Group

Dietary Supplement

Participants will take one CyanthOx™80 capsule daily for 12 weeks.

Primary outcomes

  1. Product Tolerability

    Time frame: Baseline to Week 12

    Product tolerability will be assessed by recording any adverse events reported by participants during the study. The number and percentage of participants experiencing one or more adverse events will be summarized for each group.

    unit： number and percentage of participants

  2. Participant-Reported Skin Condition and Product Satisfaction

    Time frame: Baseline, Week 4, and Week 12

    Perceived skin condition and product satisfaction will be assessed using a study-specific questionnaire with a 5-point scale, ranging from 1 to 5. Higher scores indicate greater perceived improvement or satisfaction. The percentage of participants with a score of 3 or higher will be reported.

    Unit：score

  3. Change in Blood Biomarkers (TEAC)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to antioxidant capacity using TEAC ELISA kits. Unit: percent change

  4. Change in Hair and Scalp Condition (hair-root diameter)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Changes in hair-root diameter by using Mitutoyo, C/N293-100 Unit：percent change

  5. Change in Hair and Scalp Condition (hair strength)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Changes in hair strength by using Hair Pull Test Unit：percent change

  6. Change in Hair and Scalp Condition (hair elasticity)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Changes in hair elasticity measured using SHIMADZU EZ-SX Unit：percent change

  7. Change in Hair and Scalp Condition (tensile strength)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Changes in tensile strength by using SHIMADZU EZ-SX Unit：percent change

  8. Change in Hair and Scalp Condition (hair shedding)

    Time frame: Baseline, Week 4, Week 8, and Week 12

    Changes in hair shedding by collecting and counting hairs found in the shower drain unit：percent change

  9. Change in Blood Biomarkers (SOD)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to antioxidant capacity measured using SOD ELISA kits.

    Unit: percent change

  10. Change in Blood Biomarkers (GSH)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to antioxidant capacity using GSH ELISA kits. Unit: percent change

  11. Change in Blood Biomarkers (TNF-alpha)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to inflammation measured using TNF-alpha ELISA kits.

    Unit: percent change

  12. Change in Blood Biomarkers (Desmosine)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to aging measured using Desmosine ELISA kits. Unit: percent change

  13. Change in Blood Biomarkers (AGE)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to aging measured using AGE ELISA kits. Unit: percent change

  14. Change in Blood Biomarkers (HA)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to collagen metabolism measured using TEAC HA kits.

    Unit: percent change

  15. Change in Blood Biomarkers (NAD/NADH)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to antioxidant capacity measured using NAD/NADH ELISA kits.

    Unit: percent change

  16. Change in Blood Biomarkers (Collagen)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to collagen metabolism measured using Collagen ELISA kits.

    Unit: percent change

  17. Change in Blood Biomarkers (Telomerase)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to aging, measured using Telomerase ELISA kits. Unit: percent change

  18. Change in Blood Biomarkers (CHOL)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to blood lipid metabolism measured using automated clinical chemistry analyzer.

    Unit: percent change

  19. Change in Blood Biomarkers (TEAC)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to antioxidant capacity, inflammation, aging, collagen metabolism, and blood lipid metabolism measured using TEAC ELISA kits.

    Unit: percent change

  20. Change in Blood Biomarkers (TG)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to blood lipid metabolism measured using automated clinical chemistry analyzer.

    Unit: percent change

  21. Change in Blood Biomarkers (HDL)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to blood lipid metabolism measured using automated clinical chemistry analyzer.

    Unit: percent change

  22. Change in Blood Biomarkers (LDL)

    Time frame: Baseline and Week 12

    Changes in biomarkers related to blood lipid metabolism measured using automated clinical chemistry analyzer.

    Unit: percent change

  23. Facial Skin Analysis Parameters (skin spots)

    Time frame: Baseline, Week 4, and Week 12

    VISIA Micro-Analysis Skin Image Analyzer was utilized to measure skin spots. Units: percetage change.

  24. Facial Skin Analysis Parameters (Wrinkle)

    Time frame: Baseline, Week 4, and Week 12

    VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Wrinkle. Units: percetage change.

  25. Facial Skin Analysis Parameters (Texture)

    Time frame: Baseline, Week 4, and Week 12

    VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Texture. Units: percetage change.

  26. Facial Skin Analysis Parameters (Spot)

    Time frame: Baseline, Week 4, and Week 12

    VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Spot. Units: percetage change.

  27. Facial Skin Analysis Parameters (UV Spot)

    Time frame: Baseline, Week 4, and Week 12

    VISIA Micro-Analysis Skin Image Analyzer was utilized to measure UV Spot. Units: percetage change.

  28. Facial Skin Analysis Parameters (Brown Spot)

    Time frame: Baseline, Week 4, and Week 12

    VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Brown Spot. Units: percetage change.

  29. Facial Skin Analysis Parameters (Red Area)

    Time frame: Baseline, Week 4, and Week 12

    VISIA Micro-Analysis Skin Image Analyzer was utilized to measure Red Area. Units: percetage change.

  30. Facial Skin Analysis Parameters (Collagen)

    Time frame: Baseline, Week 4, and Week 12

    DermaLab® Series SkinLab Combo was utilized to measure collagen. Units: percetage change.

  31. Facial Skin Analysis Parameters (Brightness)

    Time frame: Baseline, Week 4, and Week 12

    Chroma Meter MM500 was utilized to measure Brightness. Units: percetage change.

  32. Facial Skin Analysis Parameters (Erythema)

    Time frame: Baseline, Week 4, and Week 12

    Chroma Meter MM500 was utilized to measure Erythema. Units: percetage change.

  33. Facial Skin Analysis Parameters (Melanin)

    Time frame: Baseline, Week 4, and Week 12

    Soft Plus was utilized to measure Melanin. Units: percetage change.

  34. Facial Skin Analysis Parameters (Skin Hydration)

    Time frame: Baseline, Week 4, and Week 12

    Corneometer CM825 was utilized to measure Skin Hydration. Units: percetage change.

  35. Facial Skin Analysis Parameters (Skin Elasticity)

    Time frame: Baseline, Week 4, and Week 12

    Soft Plus was utilized to measure Skin Elasticity. Units: percetage change.

  36. Facial Skin Analysis Parameters (Transepidermal Water Loss)

    Time frame: Baseline, Week 4, and Week 12

    Tewameter TM300 was utilized to measure Transepidermal Water Loss. Units: percetage change.

Sponsors and collaborators

Lead sponsor

Chia Nan University of Pharmacy ＆ Science

Other

Registry information

Official study title

Clinical Study Plan for CyanthOx™ Hard Capsule

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 19, 2026
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.